NACL Industries Limited (NACLIND) - Net Assets
Based on the latest financial reports, NACL Industries Limited (NACLIND) has net assets worth Rs4.44 Billion INR (≈ $48.02 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs14.87 Billion ≈ $160.84 Million USD) and total liabilities (Rs10.43 Billion ≈ $112.82 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NACLIND cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs4.44 Billion |
| % of Total Assets | 29.86% |
| Annual Growth Rate | 9.33% |
| 5-Year Change | 2.02% |
| 10-Year Change | 130.06% |
| Growth Volatility | 14.66 |
NACL Industries Limited - Net Assets Trend (2006–2025)
This chart illustrates how NACL Industries Limited's net assets have evolved over time, based on quarterly financial data. Also explore NACLIND total asset value for the complete picture of this company's asset base.
Annual Net Assets for NACL Industries Limited (2006–2025)
The table below shows the annual net assets of NACL Industries Limited from 2006 to 2025. For live valuation and market cap data, see NACL Industries Limited (NACLIND) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs4.27 Billion ≈ $46.18 Million |
-16.44% |
| 2024-03-31 | Rs5.11 Billion ≈ $55.27 Million |
-10.95% |
| 2023-03-31 | Rs5.74 Billion ≈ $62.07 Million |
+17.52% |
| 2022-03-31 | Rs4.88 Billion ≈ $52.82 Million |
+16.67% |
| 2021-03-31 | Rs4.19 Billion ≈ $45.27 Million |
+17.27% |
| 2020-03-31 | Rs3.57 Billion ≈ $38.60 Million |
+25.63% |
| 2019-03-31 | Rs2.84 Billion ≈ $30.73 Million |
+18.85% |
| 2018-03-31 | Rs2.39 Billion ≈ $25.85 Million |
+7.13% |
| 2017-03-31 | Rs2.23 Billion ≈ $24.13 Million |
+20.22% |
| 2016-03-31 | Rs1.86 Billion ≈ $20.08 Million |
+4.42% |
| 2015-03-31 | Rs1.78 Billion ≈ $19.23 Million |
+1.97% |
| 2014-03-31 | Rs1.74 Billion ≈ $18.85 Million |
-10.46% |
| 2013-03-31 | Rs1.95 Billion ≈ $21.06 Million |
-6.11% |
| 2012-03-31 | Rs2.07 Billion ≈ $22.43 Million |
+2.33% |
| 2011-03-31 | Rs2.03 Billion ≈ $21.92 Million |
+0.23% |
| 2010-03-31 | Rs2.02 Billion ≈ $21.87 Million |
+33.77% |
| 2009-03-31 | Rs1.51 Billion ≈ $16.35 Million |
+36.66% |
| 2008-03-31 | Rs1.11 Billion ≈ $11.96 Million |
+19.31% |
| 2007-03-31 | Rs926.96 Million ≈ $10.02 Million |
+18.31% |
| 2006-03-31 | Rs783.51 Million ≈ $8.47 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NACL Industries Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 216900000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs2.17 Billion | 50.79% |
| Common Stock | Rs201.20 Million | 4.71% |
| Other Comprehensive Income | Rs395.40 Million | 9.26% |
| Other Components | Rs1.50 Billion | 35.24% |
| Total Equity | Rs4.27 Billion | 100.00% |
NACL Industries Limited Competitors by Market Cap
The table below lists competitors of NACL Industries Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jtekt India Limited
NSE:JTEKTINDIA
|
$408.35 Million |
|
CTOS Digital Bhd
KLSE:5301
|
$408.44 Million |
|
Prince Housing & Development Corp
TW:2511
|
$408.47 Million |
|
Gladstone Capital Corporation
NASDAQ:GLAD
|
$408.48 Million |
|
KKR Real Estate Finance Trust Inc
NYSE:KREF
|
$408.15 Million |
|
Larimar Therapeutics Inc
NASDAQ:LRMR
|
$408.15 Million |
|
Instone Real Estate Group AG
XETRA:INS
|
$408.10 Million |
|
Concord International Securities Co Ltd
TWO:5864
|
$408.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NACL Industries Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,111,000,000 to 4,270,600,000, a change of -840,400,000 (-16.4%).
- Net loss of 921,300,000 reduced equity.
- Share repurchases of 8,600,000 reduced equity.
- New share issuances of 108,600,000 increased equity.
- Other comprehensive income decreased equity by 4,399,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs-921.30 Million | -21.57% |
| Share Repurchases | Rs8.60 Million | -0.2% |
| Share Issuances | Rs108.60 Million | +2.54% |
| Other Comprehensive Income | Rs-4.40 Million | -0.1% |
| Other Changes | Rs-14.70 Million | -0.34% |
| Total Change | Rs- | -16.44% |
Book Value vs Market Value Analysis
This analysis compares NACL Industries Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.52x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 37.25x to 7.52x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs4.33 | Rs161.32 | x |
| 2007-03-31 | Rs5.12 | Rs161.32 | x |
| 2008-03-31 | Rs6.11 | Rs161.32 | x |
| 2009-03-31 | Rs8.35 | Rs161.32 | x |
| 2010-03-31 | Rs11.18 | Rs161.32 | x |
| 2011-03-31 | Rs11.20 | Rs161.32 | x |
| 2012-03-31 | Rs11.46 | Rs161.32 | x |
| 2013-03-31 | Rs12.49 | Rs161.32 | x |
| 2014-03-31 | Rs11.18 | Rs161.32 | x |
| 2015-03-31 | Rs11.40 | Rs161.32 | x |
| 2016-03-31 | Rs11.87 | Rs161.32 | x |
| 2017-03-31 | Rs14.26 | Rs161.32 | x |
| 2018-03-31 | Rs15.26 | Rs161.32 | x |
| 2019-03-31 | Rs18.13 | Rs161.32 | x |
| 2020-03-31 | Rs21.24 | Rs161.32 | x |
| 2021-03-31 | Rs21.61 | Rs161.32 | x |
| 2022-03-31 | Rs24.62 | Rs161.32 | x |
| 2023-03-31 | Rs28.85 | Rs161.32 | x |
| 2024-03-31 | Rs25.69 | Rs161.32 | x |
| 2025-03-31 | Rs21.45 | Rs161.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NACL Industries Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.46%
- • Asset Turnover: 0.98x
- • Equity Multiplier: 2.96x
- Recent ROE (-21.57%) is below the historical average (8.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 35.73% | 7.96% | 1.18x | 3.81x | Rs201.62 Million |
| 2007 | 22.90% | 6.17% | 1.12x | 3.32x | Rs119.59 Million |
| 2008 | 23.28% | 6.21% | 1.29x | 2.91x | Rs146.86 Million |
| 2009 | 32.59% | 8.14% | 1.57x | 2.56x | Rs341.50 Million |
| 2010 | 29.55% | 9.19% | 1.17x | 2.74x | Rs395.38 Million |
| 2011 | 1.52% | 0.54% | 1.03x | 2.72x | Rs-171.86 Million |
| 2012 | 3.53% | 1.14% | 1.02x | 3.04x | Rs-134.25 Million |
| 2013 | -6.51% | -2.06% | 1.02x | 3.09x | Rs-321.40 Million |
| 2014 | -11.77% | -3.23% | 1.02x | 3.56x | Rs-379.52 Million |
| 2015 | 4.69% | 1.12% | 1.12x | 3.74x | Rs-94.31 Million |
| 2016 | 5.24% | 1.41% | 1.13x | 3.29x | Rs-88.27 Million |
| 2017 | 16.64% | 5.05% | 1.11x | 2.96x | Rs148.22 Million |
| 2018 | 4.45% | 1.26% | 1.18x | 2.98x | Rs-132.77 Million |
| 2019 | -2.45% | -0.81% | 1.15x | 2.61x | Rs-353.63 Million |
| 2020 | 4.69% | 1.67% | 1.05x | 2.67x | Rs-189.56 Million |
| 2021 | 12.18% | 4.28% | 1.22x | 2.33x | Rs91.30 Million |
| 2022 | 15.03% | 4.48% | 1.09x | 3.09x | Rs245.83 Million |
| 2023 | 16.53% | 4.48% | 1.10x | 3.34x | Rs374.76 Million |
| 2024 | -11.52% | -3.31% | 0.98x | 3.56x | Rs-1.10 Billion |
| 2025 | -21.57% | -7.46% | 0.98x | 2.96x | Rs-1.35 Billion |
Industry Comparison
This section compares NACL Industries Limited's net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $13,370,134,277
- Average return on equity (ROE) among peers: 16.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NACL Industries Limited (NACLIND) | Rs4.44 Billion | 35.73% | 2.35x | $408.26 Million |
| Agro Phos India Limited (AGROPHOS) | $469.69 Million | 12.41% | 0.80x | $6.93 Million |
| Astec LifeSciences Limited (ASTEC) | $2.03 Billion | 17.62% | 1.27x | $167.40 Million |
| Bayer Cropscience Limited (BAYERCROP) | $25.24 Billion | 25.56% | 0.72x | $2.32 Billion |
| Best Agrolife Limited (BESTAGRO) | $577.23 Million | 0.02% | 0.90x | $68.89 Million |
| Bhagiradha Chemicals & Industries Limited (BHAGCHEM) | $465.11 Million | 4.24% | 1.68x | $371.49 Million |
| Bharat Rasayan Limited (BHARATRAS) | $7.27 Billion | 22.53% | 0.25x | $248.90 Million |
| Bohra Industries Limited (BOHRAIND) | $340.42 Million | 12.70% | 2.21x | $2.15 Million |
| Bombay Super Hybrid Seeds Limited (BSHSL) | $563.36 Million | 29.79% | 1.36x | $111.73 Million |
| Chambal Fertilizers & Chemicals Limited (CHAMBLFERT) | $72.58 Billion | 17.58% | 0.59x | $1.90 Billion |
| Coromandel International Limited (COROMANDEL) | $24.16 Billion | 26.44% | 2.30x | $6.32 Billion |
About NACL Industries Limited
NACL Industries Limited manufactures and sells agrochemicals in India. The company offers a range of technical products, including myclobutanil, propiconazole, profenofos, tricyclazole, pretilachlors, thiamethoxam, lambda cyhalothrin, bifenthrin, azoxystrobin, tebuconazole, difenoconazole, thifluzamide, bispyribac sodium, clodinafop propargyl, metribuzin, quizalofop ethyl, haloxyfop r methyl, and… Read more